Severe COVID-19 in Uganda Across Two Epidemic Phases: A Prospective Cohort Study
Overview
Authors
Affiliations
Among a prospective cohort of children and adults admitted to a national COVID-19 treatment unit in Uganda from March to December 2020, we characterized the epidemiology of and risk factors for severe illness. Across two epidemic phases differentiated by varying levels of community transmission, the proportion of patients admitted with WHO-defined severe COVID-19 ranged from 5% (7/146; 95% CI: 2-10) to 33% (41/124; 95% CI: 25-42); 21% (26/124; 95% CI: 14-29%) of patients admitted during the peak phase received oxygen therapy. Severe COVID-19 was associated with older age, male sex, and longer duration of illness before admission. Coinfection with HIV was not associated with illness severity; malaria or tuberculosis coinfection was rare. No patients died during admission. Despite low mortality, hospital incidence of severe COVID-19 during the first epidemic peak in Uganda was substantial. Improvements in vaccine deployment and acute care capacity, including oxygen delivery, are urgently needed to prevent and manage severe COVID-19 in sub-Saharan Africa.
Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome.
Saito S, Shahbaz S, Luo X, Osman M, Redmond D, Cohen Tervaert J Front Immunol. 2024; 15:1341843.
PMID: 38304426 PMC: 10830702. DOI: 10.3389/fimmu.2024.1341843.
Timeliness and completeness of monthly disease surveillance data reporting, Uganda, 2020-2021.
Zavuga R, Migisha R, Gonahasa D, Kadobera D, Kwesiga B, Okello P Pan Afr Med J. 2023; 46:3.
PMID: 37928222 PMC: 10620326. DOI: 10.11604/pamj.2023.46.3.40557.
Lopez-Farfan D, Yerbanga R, Parres-Mercader M, Torres-Puente M, Gomez-Navarro I, Sanou D Front Public Health. 2022; 10:1048404.
PMID: 36579069 PMC: 9791192. DOI: 10.3389/fpubh.2022.1048404.
Huluka D, Etissa E, Ahmed S, Abule H, Getachew N, Abera S Am J Trop Med Hyg. 2022; 107(2):252-259.
PMID: 35895414 PMC: 9393439. DOI: 10.4269/ajtmh.21-1270.
Olum R, Baluku J Front Public Health. 2022; 10:931309.
PMID: 35865243 PMC: 9294281. DOI: 10.3389/fpubh.2022.931309.